Q2 2021 Results - Reimagining Medicine

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References - Leqvio® – resubmission of NDA filed with FDA; preparing to launch innovative models to address access, adherence, affordability filed; PDUFA action date Jan 1, 2022 80% of patients not at goal Addressing access, adherence, affordability US ASCVD population¹ PCSK9i abandonment by OOP cost4 Progress since Q1 US: NDA resubmission 66% 41% 30m 22% 9% 0 40-50 75-125 250-500 Co-pay (USD) Diagnosed Statin treated 20m -80% At LDL-C goal² 4m Anticipated payer mix & co-pay for LeqvioⓇ at launch5 Medicare Part B (39%) 80% pay as little as 0 USD Non-statin therapy³ 1m Medicare Advantage (19%) 0-20% co-insurance Eligible patients pay as little as 0 USD <10 USD Commercial (34%) Other (8%) UK: on track for launch Q3 2021 V-INITIATE started to explore "LeqvioⓇ first" strategy directly after statins7 V-INCEPTION commenced to investigate Leqvio® initiation after recent ACS events? See slide 55 for references. ASCVD - Atherosclerotic Cardiovascular Disease LDL-C - Low Density Lipoprotein Cholesterol ACS Acute Coronary Syndrome 24 Investor Relations | Q2 2021 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation